Format

Send to

Choose Destination
Neurosci Lett. 2010 Jul 12;478(3):165-70. doi: 10.1016/j.neulet.2010.05.009. Epub 2010 May 12.

Sorafenib exerts anti-glioma activity in vitro and in vivo.

Author information

1
Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA. msiegelin@t-online.de

Erratum in

  • Neurosci Lett. 2013 Feb 28;539:93.

Abstract

Despite conventional treatment strategies glioblastoma, the most common malignant primary brain tumor, has a bad prognosis with median survival times of 12-15 months. In this study, the efficacy of sorafenib (Nexavar, BAY43-9006), a multikinase inhibitor, on glioblastoma cells was evaluated both in vitro and in vivo. Treatment of established or patient-derived glioblastoma cells with low concentrations of sorafenib caused a dramatic dose dependent inhibition of proliferation (IC(50), 1.5 microM) and induction of apoptosis and autophagy. Sorafenib inhibited phosphorylation of signal transducer and activator of transcription 3 (Stat3) and expression of cyclins, D and E. In contrast, AKT was not modulated by sorafenib. Most important, systemic delivery of sorafenib was well tolerated, and significantly suppressed intracranial glioma growth via inhibition of cell proliferation, induction of apoptosis and autophagy, and reduction of angiogenesis. Furthermore, intracranial growth inhibition by sorafenib was accompanied by a significant reduction in ph-Stat3 (Tyr 705) levels. In summary, sorafenib has potent anti-glioma activity in vitro and in vivo.

PMID:
20470863
PMCID:
PMC3198851
DOI:
10.1016/j.neulet.2010.05.009
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center